334
Views
6
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials

ORCID Icon, & ORCID Icon
Pages 455-466 | Received 03 Sep 2020, Accepted 09 Oct 2020, Published online: 26 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Alain Lescoat, John Varga, Marco Matucci-Cerinic & Dinesh Khanna. (2021) New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opinion on Investigational Drugs 30:6, pages 635-652.
Read now

Articles from other publishers (5)

Dinesh Khanna, Nancy Krieger & Keith M Sullivan. (2023) Improving outcomes in scleroderma: recent progress of cell-based therapies. Rheumatology 62:6, pages 2060-2069.
Crossref
Anna Löfdahl, Annika Nybom, Jenny Wigén, Göran Dellgren, Hans Brunnström, Christina Wenglén & Gunilla Westergren-Thorsson. (2023) Pulmonary 5-HT2B receptor expression in fibrotic interstitial lung diseases. Acta Histochemica 125:3, pages 152024.
Crossref
Sara Jaafar, Alain Lescoat, Suiyuan Huang, Jessica Gordon, Monique Hinchcliff, Ami A. Shah, Shervin Assassi, Robyn Domsic, Elana J. Bernstein, Virginia Steen, Sabrina Elliott, Faye Hant, Flavia V. Castelino, Victoria K. Shanmugam, Chase Correia, John Varga, Vivek Nagaraja, David Roofeh, Tracy Frech & Dinesh Khanna. (2021) Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Research & Therapy 23:1.
Crossref
Alain Lescoat, David Roofeh, Masataka Kuwana, Robert Lafyatis, Yannick Allanore & Dinesh Khanna. (2021) Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy & Immunology 64:3, pages 239-261.
Crossref
Michael Hughes & Dinesh Khanna. (2021) Rituximab for the treatment of systemic sclerosis: urgent need for an international randomised controlled trial. The Lancet Rheumatology 3:7, pages e463-e465.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.